Your browser doesn't support javascript.
loading
Generation and characterization of nanobodies targeting human pepsinogens.
Zhang, Shenglan; Ma, Jieyao; He, Liu; Li, Qianying; He, Pan; Li, Jing; Zhang, Huicong.
  • Zhang S; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), 510005, Guangzhou, China. Electronic address: zhang_shenglan@grmh-gdl.cn.
  • Ma J; School of Pharmaceutical Sciences, Hunan University of Medicine, 418000, Huaihua, China.
  • He L; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), 510005, Guangzhou, China.
  • Li Q; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), 510005, Guangzhou, China.
  • He P; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), 510005, Guangzhou, China.
  • Li J; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), 510005, Guangzhou, China.
  • Zhang H; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), 510005, Guangzhou, China.
Protein Expr Purif ; 216: 106431, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38184161
ABSTRACT
Human pepsinogens (mainly pepsinogen I and pepsinogen II) are the major inactive precursor forms of the digestive enzyme pepsin which play a crucial role in protein digestion. The levels and ratios of human pepsinogens have demonstrated potential as diagnostic biomarkers for gastrointestinal diseases, particularly gastric cancer. Nanobodies are promising tools for the treatment and diagnosis of diseases, owing to their unique recognition properties. In this study, recombinant human pepsinogens proteins were expressed and purified as immunized antigens. We constructed a VHH phage library and identified several nanobodies via phage display bio-panning. We determined the binding potency and cross-reactivity of these nanobodies. Our study provides technical support for developing immunodiagnostic reagents targeting human pepsinogens.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pepsinógenos / Anticuerpos de Dominio Único Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pepsinógenos / Anticuerpos de Dominio Único Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article